Clinical trial
STA-4783 and Paclitaxel for Treatment of Solid Tumors
NCT00088114 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00088114 |
|---|---|
| Title | STA-4783 and Paclitaxel for Treatment of Solid Tumors |
| Official title | A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | STA-4783/paclitaxel |
| Enrollment | 50 |
| Start date | Jan 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Jul 21, 2004 |
| Last update posted | Mar 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: